vimarsana.com

Page 56 - ஆரோக்கியம் ஆஃப் தி ரஷ்ய கூட்டமைப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sputnik V vaccine efficacy confirmed at 91 4 per cent during Phase 3 trials

Sputnik V vaccine efficacy confirmed at 91.4 per cent during Phase 3 trials ANI | Updated: Dec 14, 2020 22:34 IST Moscow [Russia], December 14 (ANI): The efficacy of the Sputnik VCOVID-19 vaccine has been confirmed to be 91.4 per cent, based on data analysis of the final control point of clinical trials, announced the Gamaleya National Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) on Monday. According to a joint statement, the Gamaleya Center and RDIF announced the efficacy of over 90 per cent, as demonstrated by the final control point data analysis of the largest double-blind, randomised, placebo-controlled Phase 3 post-registration clinical trials of the Sputnik V vaccine against the novel coronavirus.

Sputnik V vaccine s efficacy confirmed at 91 4 pc: RDIF, Gamaleya Center

NEW DELHI, Dec 14: Russia’s Sputnik V vaccine is 91.4 per cent effective in providing protection against COVID-19 and has demonstrated 100 per cent efficacy against severe coronavirus cases, the vaccine’s developers said on Monday. “The efficacy of the Sputnik V vaccine is 91.4 per cent, based on the final control point analysis of data obtained 21 days after administering the first dose,” Gamaleya Center and the Russian Direct Investment Fund (RDIF) said in a statement. The vaccine demonstrated 100 per cent efficacy against severe coronavirus cases, it added. Based on the data obtained at the third control point, the Gamaleya Center will create a report that will be used to submit for accelerated registration of the Sputnik V vaccine in various countries, the statement said.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.